Heart Closure Devices Market - By Product (Atrial Septal Defect (ASD) Closure Devices, Left Atrial Appendage (LAA) Closure Devices), By Material (Nitinol-based Devices, Stainless Steel Devices), Mode of Delivery, End-use & Forecast, 2023

Description

List of Tables

Global Heart Closure Devices Market will witness a 12.2% CAGR between 2023 and 2032. The rising incidence of cardiovascular diseases worldwide has propelled the demand for minimally invasive procedures. According to WHO, each year, cardiovascular diseases (CVDs) are responsible for approximately 17.9 million fatalities worldwide, solidifying their position as the leading cause of death.

Procedures like percutaneous closure of atrial septal defects and patent foramen ovale propel the need for heart closure devices. Additionally, technological advancements have improved the safety and efficacy of these devices, attracting both patients and healthcare providers, thus contributing to market growth. Moreover, the increasing aging population and growing awareness of the benefits of these devices will strengthen the heart closure devices market outlook through 2032.

The overall Heart Closure Devices Market is classified based on product, material, end-use, and region.

With respect to product, the Atrial Septal Defect (ASD) segment will expand at a 12.6% CAGR from 2023 to 2032. ASD is a congenital heart condition in which a hole exists between the atria, leading to abnormal blood flow. These devices, such as septal occluders, offer a minimally invasive solution to close the defect, reducing the risk of complications and improving patients' quality of life. With growing awareness of ASD and advancements in device technology, the demand for heart closure devices in managing this condition is steadily increasing.

By material, the other segment will register a 12.5% CAGR from 2023 to 2032. The need for improved biocompatibility and reduced risk of allergies or adverse reactions in patients is driving segment growth. Materials like bioabsorbable polymers and titanium alloys are gaining popularity due to their favorable attributes. These materials not only enhance patient safety but also offer innovative solutions for minimally invasive procedures, expanding the market's scope beyond traditional choices.

Regarding the end-use, the cardiac catheterization laboratories segment will exhibit a 12.3% CAGR over 2023-2032. Cardiac catheterization labs are at the forefront of minimally invasive cardiac procedures. Heart closure devices, like septal occluders and vascular plugs, are increasingly utilized in such settings to treat conditions like atrial septal defects and patent foramen ovale. Their effectiveness, safety, and reduced recovery times make them essential tools in these specialized facilities.

Regionally, the Asia Pacific heart closure devices market will record a 13.3% CAGR from 2023 to 2032. The market is thriving due to the increasing prevalence of cardiovascular diseases in countries driving the need for minimally invasive treatment options. Additionally, improving healthcare infrastructure and rising healthcare awareness, in line with the growing aging population, are contributing to the market expansion. As the Asia-Pacific region continues to prioritize cardiovascular health, the heart closure devices market revenue is set for substantial growth in the coming years.

Product Code: 6140

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Heart closure devices industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Product trends
2.5 Material trends
2.6 Mode of delivery trends
2.7 End-use trends

Chapter 3 Heart Closure Devices Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of cardiovascular diseases
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rising preference for minimally invasive procedures
  - 3.2.1.4 Favorable reimbursement policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory policies
  - 3.2.2.2 Potential complications and adverse events
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By material
- 3.3.3 By mode of delivery
- 3.3.4 By end-use
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Reimbursement scenario
3.7 Pricing analysis, 2022
3.8 Technology landscape
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard, 2022

Chapter 5 Heart Closure Devices Market Size and Forecast, By Product (USD Million & Units)

5.1 Key product trends
5.2 Atrial Septal Defect (ASD) Closure Devices
5.3 Ventricular Septal Defect (VSD) Closure Devices
5.4 Patent Foramen Ovale (PFO) Closure Devices
5.5 Left Atrial Appendage (LAA) Closure Devices
5.6 Others

Chapter 6 Heart Closure Devices Market Size and Forecast, By Material (USD Million)

6.1 Key material trends
6.2 Nitinol-based Devices
6.3 Stainless Steel Devices
6.4 Others

Chapter 7 Heart Closure Devices Market Size and Forecast, By Mode of Delivery (USD Million)

7.1 Key mode of delivery trends
7.2 Transcatheter Delivery
7.3 Surgical Delivery

Chapter 8 Heart Closure Devices Market Size and Forecast, By End-use (USD Million)

8.1 Key end-use trends
8.2 Hospitals
8.3 Ambulatory Surgical Centers (ASCs)
8.4 Cardiac Catheterization Laboratories
8.5 Others

Chapter 9 Heart Closure Devices Market Size and Forecast, By Region (USD Million & Units)

9.1 Key regional trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Sweden
- 9.3.8 The Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Philippines
- 9.4.8 Vietnam
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Columbia
- 9.5.5 Chile
- 9.5.6 Peru
9.6 Middle East & Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Turkey
- 9.6.5 Iran
- 9.6.6 Israel

Chapter 10 Company Profiles

10.1 Abbott Laboratories
10.2 AtriCure Inc.
10.3 Biosense Webster, Inc.
10.4 Boston Scientific Corporation
10.5 Cardia, Inc.
10.6 Heartstitch
10.7 Lepu Medical Technology (Beijing)Co., Ltd.
10.8 LifeTech Scientific Corporation
10.9 Medtronic Plc.
10.10 Occlutech
10.11 SentreHEART, Inc.
10.12 Starway Medical Technology, Inc.
10.13 W. L. Gore & Associates, Inc.